{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:19:27Z","timestamp":1763011167595,"version":"3.45.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Hematol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the Portuguese experience with the use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma since its approval in the country.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter retrospective cohort of patients with mantle cell lymphoma who received ibrutinib between 2015 and 2020 was studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-five patients treated at 11 hospitals were included. At the ibrutinib starting date, 51% of patients had high-risk simplified mantle cell lymphoma international prognostic index, 9% had central nervous system involvement, and 21% had Eastern Cooperative Oncology Group performance status \u22652. The median treatment duration was 10 (&amp;lt;1-75) months. The overall response rate was 66%, including 36% with complete responses. After 18 months of follow-up, seventy-two patients (76%) had discontinued ibrutinib, mainly due to progressive disease (61%) and toxicity (21%). At the last follow-up, 24% of patients were still on ibrutinib, and 60% had died, mostly (65%) due to lymphoma progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world series, the safety of ibrutinib is similar to the results described in clinical trials. However, new strategies are needed for the treatment of acquired resistance to ibrutinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frhem.2025.1702446","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:16:09Z","timestamp":1763010969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Portuguese real-world experience with ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma"],"prefix":"10.3389","volume":"4","author":[{"given":"Catarina","family":"Fernandes","sequence":"first","affiliation":[]},{"given":"Rita","family":"Costa e Sousa","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Santos","sequence":"additional","affiliation":[]},{"given":"C\u00e1tia","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Adriana","family":"Roque","sequence":"additional","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joaquim","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Anabela","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Coutinho","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Mousinho","sequence":"additional","affiliation":[]},{"given":"Mariana Leal","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Badior","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Jo\u00e3o","sequence":"additional","affiliation":[]},{"given":"S\u00f3nia","family":"Leoc\u00e1dio","sequence":"additional","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Tom\u00e9","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Carrolo","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Maria Gomes","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Paulo","family":"Fernandes","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic Malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25215","article-title":"Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed\/refractory mantle cell lymphoma","volume":"9","author":"Broccoli","year":"2018","journal-title":"Oncotarget"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17363","article-title":"Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients","volume":"193","author":"McCulloch","year":"2021","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines\u00ae Insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: A pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"HemaSphere"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023525","article-title":"Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study","volume":"144","author":"Malinverni","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","article-title":"Ibrutinib in patients with relapsed\/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the \"RTL\" (regional Tuscan lymphoma network)","volume":"11","author":"Cencini","year":"2021","journal-title":"Am J Blood Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40360-024-00832-9","article-title":"Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies","volume":"26","author":"Karimi","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283802","article-title":"Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2022-163018","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Hematology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhem.2025.1702446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:16:09Z","timestamp":1763010969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhem.2025.1702446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":17,"alternative-id":["10.3389\/frhem.2025.1702446"],"URL":"https:\/\/doi.org\/10.3389\/frhem.2025.1702446","relation":{},"ISSN":["2813-3935"],"issn-type":[{"value":"2813-3935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"article-number":"1702446"}}